Jupiter Neurosciences Inc (JUNS)

$JUNS This turd is shorts heaven ! 🤦

$JUNS Sold with 50% loss ! Fuck this shit 🤦🤦

$JUNS Why this piece of shit keeps digging every day ?

$JUNS Shorted this garbage yesterday. Will cover at .50

bought $JUNS at .60

TAOP stock is the next big squeezer, upcoming robotics acquisition with no dilution and a small 1m micro float. These are the types that can go 500% $SXTP $SXTC $FEAM $JUNS $HIND

$JUNS Nail in the coffin for this ticker

$JUNS I hope you shorts get cooked like $BNAI over here 🙏🙏

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS) announced a strategic initiative to support individuals using GLP-1-based weight loss therapies through its Nugevia™ consumer longevity product line. Jupiter Neurosciences, Inc. is a B2i Digital Featured Company. A full company profile will be available soon at https://b2idigital.com/featured-companies. The initiative reinforces Jupiter’s dual-engine strategy, combining a clinical-stage pharmaceutical pipeline with a direct-to-consumer longevity business. As global adoption of GLP-1 therapies accelerates, Jupiter is positioning Nugevia™ to address biological stresses that can accompany rapid metabolic change. The initiative targets: • Mitochondrial energy production, neuro-inflammatory balance, and metabolic resilience • Positioning Nugevia™ for a growing population using GLP-1 therapies • Leveraging Jupiter’s proprietary resveratrol-based delivery technology across consumer and pharmaceutical applications “GLP-1 therapies drive weight loss, but biology still must sustain it. The Aesthetic Surgery Journal recently reported that patients with significant weight loss may look up to 5 years older than peers without such weight changes and an increase of 4,600% of the search term ‘Ozempic face’ on the internet. Using AI we have found that a combination of our Nugevia™ MND and Nugevia™ PWR products is indicated to be a possible solution to avoid this issue,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. Read the full press release: https://jupiterneurosciences.com/press-releases/?i=161566 Based in Jupiter, Florida, Jupiter Neurosciences is a clinical-stage pharmaceutical company built around JOTROL™, a patented resveratrol formulation that has demonstrated nine times greater bioavailability than earlier versions of the compound. The company operates a dual-path business model: advancing a therapeutic pipeline targeting neuroinflammation and CNS disorders while commercializing Nugevia™, a premium longevity supplement line using the same delivery technology. The company is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; Marshall Hayward, Ph.D., Co-Founder and CSO; Alexander Rosén, Co-Founder and CAO; Dr. Claes Wahlestedt, MD, Ph.D., Co-Founder and Consulting CMO; and Shaun P. Brothers, Ph.D., Co-Founder and Consulting Head of Scientific Research. To learn more about Jupiter Neurosciences, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com.